StockData
Definium Therapeutics, Inc. logo

Definium Therapeutics, Inc. (DFTX) stock

DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$32.08−0.92 (-2.79%)

Close on Nov 13, 2026Market cap $4.31BP/E –Yield –

Definium Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Definium Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$191.36M. For fiscal 2025 it was -$131.56M. The highest annual figure on record is -$23.60M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$131.56M–
FY2024Dec 31, 2024-$79.13M–
FY2023Dec 31, 2023-$64.37M–
FY2022Dec 31, 2022-$50.14M–
FY2021Dec 31, 2021-$45.82M–
FY2020Dec 31, 2020-$23.60M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$52.98M–
Q2 FY2026Jun 30, 2026-$52.78M–
Q1 FY2026Mar 31, 2026-$42.63M–
Q4 FY2025Dec 31, 2025-$42.98M–
Q3 FY2025Sep 30, 2025-$29.57M–
Q2 FY2025Jun 30, 2025-$29.60M–
Q1 FY2025Mar 31, 2025-$29.42M–
Q4 FY2024Dec 31, 2024-$25.35M–
Q3 FY2024Sep 30, 2024-$17.19M–
Q2 FY2024Jun 30, 2024-$19.99M–
Q1 FY2024Mar 31, 2024-$16.60M–
Q4 FY2023Dec 31, 2023-$20.56M–
Q3 FY2023Sep 30, 2023-$16.63M–
Q2 FY2023Jun 30, 2023-$13.85M–
Q1 FY2023Mar 31, 2023-$13.33M–
Q4 FY2022Dec 31, 2022-$12.85M–
Q3 FY2022Sep 30, 2022-$9.30M–
Q2 FY2022Jun 30, 2022-$15.13M–
Q1 FY2022Mar 31, 2022-$12.87M–
Q4 FY2021Dec 31, 2021-$7.83M–
Q3 FY2021Sep 30, 2021-$16.78M–
Q2 FY2021Jun 30, 2021-$11.17M–
Q1 FY2021Mar 31, 2021-$10.04M–

More Definium Therapeutics figures

See a number that looks wrong?